Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Study links decreased deep sleep to early signs

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
raja48185 Member Profile
 
Followed By 27
Posts 5,074
Boards Moderated 0
Alias Born 05/18/07
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
raja48185   Thursday, 01/10/19 08:47:15 PM
Re: None
Post # of 237167 
Study links decreased deep sleep to early signs of Alzheimer's disease


http://www.xinhuanet.com/english/2019-01/11/c_137735079.htm

CHICAGO, Jan. 10 (Xinhua) -- Researchers at Washington University School of Medicine in St. Louis found that older people who have less slow-wave sleep, the deep sleep one needs to consolidate memories and wake up feeling refreshed, have higher levels of the brain protein tau, and elevated tau is a sign of Alzheimer's disease and has been linked to brain damage and cognitive decline.

To better understand the link between sleep and Alzheimer's disease, the researchers studied 119 people aged above 60 or older, of which 80 percent were cognitively normal, and the remainder were very mildly impaired.

The researchers monitored the participants' sleep at home over the course of a normal week. Participants were given a portable EEG monitor that strapped to their foreheads to measure their brain waves as they slept, as well as a wristwatch-like sensor that tracks body movement. They also kept sleep logs, where they made note of both nighttime sleep sessions and daytime napping. Each participant produced at least two nights of data, some had as many as six.

The researchers also measured levels of amyloid beta and tau in the brain and in the cerebrospinal fluid that bathes the brain and spinal cord. Thirty-eight people underwent PET brain scans for the two proteins; 104 people underwent spinal taps to provide cerebrospinal fluid for analysis; and 27 did both.

After controlling for factors such as sex, age and movements while sleeping, the researchers found that decreased slow-wave sleep coincided with higher levels of tau in the brain and a higher tau-to-amyloid ratio in the cerebrospinal fluid.

"The key is that it wasn't the total amount of sleep that was linked to tau, it was the slow-wave sleep, which reflects quality of sleep," said first author Brendan Lucey, an assistant professor of neurology and director of the Washington University Sleep Medicine Center. "The people with increased tau pathology were actually sleeping more at night and napping more in the day, but they weren't getting as good quality sleep."

The brain changes that lead to Alzheimer's, a disease that affects an estimated 5.7 million Americans, start slowly and silently. It takes up to two decades before the characteristic symptoms of memory loss and confusion appear, and amyloid beta protein begins to collect into plaques in the brain.

"Measuring how people sleep may be a noninvasive way to screen for Alzheimer's disease before or just as people begin to develop problems with memory and thinking," Lucey said.

Nonetheless, the researchers don't expect sleep monitoring to replace brain scans or cerebrospinal fluid analysis for identifying early signs of Alzheimer's disease, though it could supplement them.

The findings were published on Jan. 9 in Science Translational Medicine.

ADXS Business Plan for 2019 : Raising more capital
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist